tVNS Effects on Motivation in Depression

Sponsor
University Hospital Tuebingen (Other)
Overall Status
Completed
CT.gov ID
NCT05120336
Collaborator
Universität Tübingen (Other)
67
1
4
13.6
4.9

Study Details

Study Description

Brief Summary

Attaining goals or rewards commonly entails response costs. In light of cost and benefits, how do participants decide what effort should be put in to give it a shot? Figuratively, you may "go with your gut", but the literal contribution of the gut-brain axis in allocating effort is poorly understood to date. Here, the investigators propose to investigate non-invasive transcutaneous vagal nerve stimulation (tVNS) as a potential modulator of energy metabolism and response vigor. Since the neural mechanisms causing the diverse cognitive and behavioral effects of the stimulation remain largely elusive, the investigators will use computational modeling of instrumental behavior and determine the primary metabolic effects of the stimulation. The investigators hypothesize that tVNS will lead to activation of afferent targets in the brain. In turn, the elicited brain activation is expected to mediate the cognitive effects of the stimulation. This may affect both sides of the utility equation because anti-depressive effects may correspond to boosting the benefit of effort whereas anti-nociceptive effects may reduce perceived costs of effort. Collectively, dissecting the cognitive effects of non-invasive tVNS in healthy individuals may facilitate the more widespread use as a treatment in mental disorders that are characterized by metabolic alterations such as depression.

Condition or Disease Intervention/Treatment Phase
  • Device: transcutaneous vagus nerve stimulation
  • Device: sham stimulation
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
67 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Primary Purpose:
Basic Science
Official Title:
The Effects of Transcutaneous Vagus Nerve Stimulation on Motivation in Major Depressive Disorder
Actual Study Start Date :
Dec 11, 2019
Actual Primary Completion Date :
Jan 29, 2021
Actual Study Completion Date :
Jan 29, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Non-depressed control participants: sham first, active taVNS second

Non-depressed control participants receive sham stimulation in the first session (biphasic stimulation with a frequenyc of 25 Hz, 30s OFF/30s ON at the earlobe (sham) for 1.5 h). In a second identical session, they receive active stimulation with the same parameters (at the cymba conchae).

Device: transcutaneous vagus nerve stimulation
Non-invasive brain stimulation technique that is used to stimulate vagal afferent projections to the nucleus of the solitary tract. Invasive VNS has been approved for the treatment of treatment-resistant depression.
Other Names:
  • transcutaneous auricular vagus nerve stimulation
  • Device: sham stimulation
    Sham procedure for active transcutaneous vagus nerve stimulation
    Other Names:
  • transcutaneous stimulation of the earlobe
  • Experimental: Patients with major depressive disorders: sham first, active taVNS second

    participants with depression receive sham stimulation in the first session (biphasic stimulation with a frequenyc of 25 Hz, 30s OFF/30s ON at the earlobe (sham) for 1.5 h). In a second identical session, they receive active stimulation with the same parameters (at the cymba conchae).

    Device: transcutaneous vagus nerve stimulation
    Non-invasive brain stimulation technique that is used to stimulate vagal afferent projections to the nucleus of the solitary tract. Invasive VNS has been approved for the treatment of treatment-resistant depression.
    Other Names:
  • transcutaneous auricular vagus nerve stimulation
  • Device: sham stimulation
    Sham procedure for active transcutaneous vagus nerve stimulation
    Other Names:
  • transcutaneous stimulation of the earlobe
  • Experimental: Patients with major depressive disorders: active taVNS first, sham second

    participants with depression receive active stimulation in the first session (biphasic stimulation with a frequenyc of 25 Hz, 30s OFF/30s ON at the cymba conchae (active) for 1.5 h). In a second identical session, they receive sham stimulation with the same parameters (at the earlobe).

    Device: transcutaneous vagus nerve stimulation
    Non-invasive brain stimulation technique that is used to stimulate vagal afferent projections to the nucleus of the solitary tract. Invasive VNS has been approved for the treatment of treatment-resistant depression.
    Other Names:
  • transcutaneous auricular vagus nerve stimulation
  • Device: sham stimulation
    Sham procedure for active transcutaneous vagus nerve stimulation
    Other Names:
  • transcutaneous stimulation of the earlobe
  • Experimental: Non-depressed control participants: active taVNS first, sham second

    Non-depressed control participants receive active stimulation in the first session (biphasic stimulation with a frequenyc of 25 Hz, 30s OFF/30s ON at the cymba conchae (active) for 1.5 h). In a second identical session, they receive sham stimulation with the same parameters (at the earlobe).

    Device: transcutaneous vagus nerve stimulation
    Non-invasive brain stimulation technique that is used to stimulate vagal afferent projections to the nucleus of the solitary tract. Invasive VNS has been approved for the treatment of treatment-resistant depression.
    Other Names:
  • transcutaneous auricular vagus nerve stimulation
  • Device: sham stimulation
    Sham procedure for active transcutaneous vagus nerve stimulation
    Other Names:
  • transcutaneous stimulation of the earlobe
  • Outcome Measures

    Primary Outcome Measures

    1. Food reward ratings [during stimulation (compared to sham)]

      Operationalized via visual analogue scale ratings of liking [-100 - 100] and wanting [0-100] in a food cue reactivity task

    2. Motivation to work for rewards: frequency of button presses to gain food an monetary rewards [during stimulation (compared to sham)]

      Operationalized via the relative frequency of button presses on an Xbox controller in an effort allocation task during either the first seconds of each trial (invigoration) or each complete trial (maintenance)

    3. Reward learning: correct choices [during stimulation (compared to sham)]

      Operationalized via number of correct value-based choices in a valenced go/no-go learning task

    4. Positive and negative mood [Pre stimulation and 20 minutes post stimulation (compared to sham)]

      Operationalized via visual analogue ratings (0-100) of positive and negative affect schedule mood items

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • 30 kg/m2 > BMI > 18.5 kg/m2
    Exclusion Criteria:

    lifetime

    • brain injury

    • coronary heart disease and occurred apoplexy

    • schizophrenia

    • bipolar disorder

    • implants (e.g., cochlea implant)

    • asthma

    12 month

    • severe substance use disorders (DSM-V), except tobacco

    • obessive compulsive disorder

    • somatic symptom disorder

    • eating disorder

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Psychiatry & Psychotherapy, University of Tübingen Tübingen BW Germany 72076

    Sponsors and Collaborators

    • University Hospital Tuebingen
    • Universität Tübingen

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital Tuebingen
    ClinicalTrials.gov Identifier:
    NCT05120336
    Other Study ID Numbers:
    • NBK_TUE004
    First Posted:
    Nov 15, 2021
    Last Update Posted:
    Dec 8, 2021
    Last Verified:
    Oct 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital Tuebingen
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 8, 2021